Sign in
Taking people in United StatesPhase 4

Tests estrogen skin patches for bone health in young women with cystic fibrosis

Tests estrogen skin patches in young women with cystic fibrosis and low estrogen.

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, United StatesSee the site
Trial code
Registry title
Estrogen Supplementation and Bone Health in Women With CF
Status
Recruiting
Phase
Phase 4
People taking part
75 people, planned
Started
2 May 2023
Expected to end
Jan 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Transdermal estrogen
  • Progesterone
Record updated
14 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for girls and women with cystic fibrosis (CF) who have had at least 1 menstrual period. It studies how hormone treatment affects bone health.

Age
Observational study: no age limit given in the criteria. Feasibility sub-study: under 35 years old.
Sex
Female only.
Disease stage
Cystic fibrosis. For the sub-study: symptoms of low estrogen and/or low blood estradiol (< 50 pg/mL), and at least 2 years since the first menstrual cycle.
Earlier treatment
Planning to use the same estrogen treatment (or none) for the whole study. Sub-study: no current systemic estrogen, no previous lung or liver transplant, no long-term systemic glucocorticoids, no anti-osteoporosis treatment.
Biomarker or test result
Sub-study: low estradiol (< 50 pg/mL) or symptoms of low estrogen.

Main reasons for not taking part

  • Taking anti-osteoporosis medicine such as bisphosphonates, teriparatide or denosumab
  • Pregnant or planning to become pregnant
  • Conditions with expected bone loss, such as breastfeeding
  • Sub-study: history of blood clots or other clotting risks
  • Sub-study: pulmonary exacerbation now, or antibiotics for one in the past 4 weeks

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • CF Diagnosis
  • Females who have had at least 1 menstrual cycle
  • Planning to use same formulation of estrogen supplementation (or none) for duration of study
  • All of above and
  • <35 years old
  • At least 2 years after first menstrual cycle
  • Symptoms of low estrogen and/or low serum estradiol levels (< 50 pg/mL)

Who cannot take part

  • Use of anti-osteoporosis therapy including anti-resorptives such as bisphosphonates or anabolic agents such as teriparatide or denosumab
  • Previous lung or liver transplant
  • Conditions increasing risk of clot: history of previous deep vein thrombus or pulmonary embolism, current immobility, current peripherally inserted central catheter or mediport, known hypercoagulable condition
  • Conditions in which bone loss is known to be present or expected to occur, such as lactation
  • Severe vitamin D deficiency (serum 25(OH)D < 6 ng/mL)
  • Pregnant or planning to become pregnant
  • In the opinion of the CF care team or study investigators participant should not participate in the study
  • Inability to provide informed consent/assent; Feasibility Sub-Study:
  • All of above and
  • Contraindications to transdermal estradiol
  • Current use of systemic estrogen (such as estrogen-containing oral contraceptive pill)
  • Use of chronic systemic glucocorticoids
  • Baseline study visit falls between 1 and 8 weeks after initiation of CF transmembrane receptor (CFTR) modulator
  • Currently in pulmonary exacerbation
  • Recent antibiotic use within the past 4 weeks for an acute pulmonary exacerbation
  • Unwilling or unable to use a non-estrogen containing method of contraception such as barrier, abstinence, or progesterone-only method

Other criteria

  • Observational Study:

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 0 and 100 years old?

Where in United States

  • Johns HopkinsBaltimore, United StatesContact: Cynthia WangTaking people

About the trial

What the trial wants to find out

The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF). The study has two main components, an observational study and a feasibility sub-study. The main questions it aims to answer are:

Read full original descriptionShow less

* How do different forms of hormonal contraception (e.g. birth control pill or other progesterone only methods) impact bone health? * Is a study of transdermal estradiol (estrogen skin patches) feasible in this group? * How does transdermal estradiol impact bone health and quality of life?

Participants in the observational study will have three study visits (baseline, 6 months, and 12 months). At all visits, participants will have blood drawn and will complete questionnaires. At the baseline and 12 month visits, participants will additionally have x-rays and DXAs (bone density assessment). Between visits, participants will complete brief questionnaires. Researchers will compare various measurements over time to assess the impact of different forms of hormonal contraception.

Participants in the feasibility sub-study will apply transdermal estradiol patches once weekly for 12 months, fill out brief quality-of-life surveys in between study visits, and complete blood draws and questionnaires at four study visits (baseline, 3 months, 6 months, and 12 months). The participants will also have x-rays and DXAs performed at the baseline and 12 month visits. Researchers will examine changes in various measurements to determine the impact of transdermal estradiol.

The 2 groups in the trial

  • Observational StudyNo study treatment, for comparison

    Participants will complete three study visits (baseline, 6 months, and 12 months) involving DXAs (bone density assessment), x-rays, blood draws, and questionnaires.

  • Transdermal Estradiol/Cyclic ProgesteroneTreatment being tested

    Participants will apply transdermal estradiol patches (0.1 mg/day) weekly for 12 months following baseline study visits. Participants not already using a progesterone-containing contraceptive will also take progesterone (200 mg) for 10 days per month.

    Treatment: Transdermal estrogen and Progesterone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Estrogen Supplementation and Bone Health in Women With CF (STURDY)
Plain-language title
Tests estrogen skin patches for bone health in young women with cystic fibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05704036, who can take part
Record updated
14 November 2025